CN102939290B - 2,3-二氢-1h-茚-1-基-2,7-二氮杂螺[3.5]壬烷衍生物及其作为生长激素释放肽受体的拮抗剂或反向激动剂的用途 - Google Patents

2,3-二氢-1h-茚-1-基-2,7-二氮杂螺[3.5]壬烷衍生物及其作为生长激素释放肽受体的拮抗剂或反向激动剂的用途 Download PDF

Info

Publication number
CN102939290B
CN102939290B CN201180014627.7A CN201180014627A CN102939290B CN 102939290 B CN102939290 B CN 102939290B CN 201180014627 A CN201180014627 A CN 201180014627A CN 102939290 B CN102939290 B CN 102939290B
Authority
CN
China
Prior art keywords
dihydro
diazaspiro
inden
nonane
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180014627.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102939290A (zh
Inventor
S·K·巴塔查亚
K·O·卡梅隆
D·P·费尔南多
D·W-S·孔
A·T·隆德雷甘
K·F·麦克卢尔
S·T·M·希米拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN102939290A publication Critical patent/CN102939290A/zh
Application granted granted Critical
Publication of CN102939290B publication Critical patent/CN102939290B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4747Quinolines; Isoquinolines spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180014627.7A 2010-03-19 2011-03-11 2,3-二氢-1h-茚-1-基-2,7-二氮杂螺[3.5]壬烷衍生物及其作为生长激素释放肽受体的拮抗剂或反向激动剂的用途 Expired - Fee Related CN102939290B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31552210P 2010-03-19 2010-03-19
US61/315,522 2010-03-19
US201161444401P 2011-02-18 2011-02-18
US61/444,401 2011-02-18
PCT/IB2011/051035 WO2011114271A1 (en) 2010-03-19 2011-03-11 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor

Publications (2)

Publication Number Publication Date
CN102939290A CN102939290A (zh) 2013-02-20
CN102939290B true CN102939290B (zh) 2015-09-16

Family

ID=44647714

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180014627.7A Expired - Fee Related CN102939290B (zh) 2010-03-19 2011-03-11 2,3-二氢-1h-茚-1-基-2,7-二氮杂螺[3.5]壬烷衍生物及其作为生长激素释放肽受体的拮抗剂或反向激动剂的用途

Country Status (26)

Country Link
US (2) US8609680B2 (https=)
EP (1) EP2547679B1 (https=)
JP (1) JP5496409B2 (https=)
KR (1) KR101455917B1 (https=)
CN (1) CN102939290B (https=)
AR (1) AR080688A1 (https=)
AU (1) AU2011228699B2 (https=)
BR (1) BR112012023664B1 (https=)
CA (1) CA2792234C (https=)
CY (1) CY1118721T1 (https=)
DK (1) DK2547679T3 (https=)
ES (1) ES2557895T3 (https=)
HR (1) HRP20151232T1 (https=)
HU (1) HUE025774T2 (https=)
IL (1) IL221952A (https=)
ME (1) ME02330B (https=)
MX (1) MX2012010772A (https=)
PH (1) PH12012501800A1 (https=)
PL (1) PL2547679T3 (https=)
PT (1) PT2547679E (https=)
RS (1) RS54383B1 (https=)
RU (1) RU2524341C2 (https=)
SG (1) SG183812A1 (https=)
SI (1) SI2547679T1 (https=)
TW (1) TWI410423B (https=)
WO (1) WO2011114271A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334193A (zh) 2012-06-04 2015-02-04 辉瑞大药厂 生长激素释放肽受体反向激动剂或拮抗剂用于治疗睡眠障碍的用途
IN2014DN09346A (https=) 2012-06-13 2015-07-17 Hoffmann La Roche
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1,2-c;3,4-c’]二吡咯-2基
HUE038764T2 (hu) 2014-03-17 2018-11-28 Remynd Nv 2,7-Diazaspiro[3.5]nonán vegyületek
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
CN106749002A (zh) * 2015-02-12 2017-05-31 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
KR102882225B1 (ko) 2017-02-21 2025-11-07 엘지전자 주식회사 냉장고
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
SG11201908560SA (en) 2017-03-16 2019-10-30 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors
AU2018306619B2 (en) 2017-07-28 2022-06-02 Chemocentryx, Inc. Immunomodulator compounds
CN108588215A (zh) * 2018-05-03 2018-09-28 成都中创清科医学检验所有限公司 一种用于检测家族性高胆固醇血症易感性相关的snp位点的引物及其检测方法
CN109970631A (zh) * 2019-03-26 2019-07-05 上海吉奉生物科技有限公司 一种5-碘-2-吡啶乙酸的合成方法
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CN111777559B (zh) * 2019-04-23 2021-11-09 苏州大学 基于端炔制备多取代吡唑的方法
CN110172062B (zh) * 2019-06-21 2022-01-07 南京药石科技股份有限公司 一种单氟代螺环化合物的合成方法及其中间体
WO2021030552A1 (en) * 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
US20240246959A1 (en) 2020-11-27 2024-07-25 Shenzhen Salubris Pharmaceuticals Co., Ltd. Benzimidazole derivative and preparation method therefor and medical use thereof
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
KR20220001745U (ko) 2021-01-06 2022-07-13 성보라 자동차시트 후면 보호용 보조커버
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898239A (zh) * 2003-10-23 2007-01-17 阿斯利康(瑞典)有限公司 新的二氮杂螺烷及其在治疗ccr8介导的疾病中的用途
WO2007007069A1 (en) * 2005-07-07 2007-01-18 Vernalis (R & D) Limited Azacyclic compounds as inhibitors of sensory neurone specific sodium channels
CN101541795A (zh) * 2006-09-15 2009-09-23 先灵公司 用于治疗疼痛、糖尿病和脂类代谢紊乱的螺-稠合氮杂环丁烷衍生物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
IL157253A0 (en) 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
KR100869616B1 (ko) 2004-05-12 2008-11-21 화이자 프로덕츠 인코포레이티드 프롤린 유도체 및 그의 다이펩티딜 펩티다제-iv저해제로서의 용도
UA84208C2 (en) 2004-05-25 2008-09-25 Пфайзер Продактс Инк. Tetraazabenzo(e)azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
MX2008008340A (es) 2005-12-21 2008-09-03 Schering Corp Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
JP5190448B2 (ja) 2006-04-20 2013-04-24 ファイザー・プロダクツ・インク グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物
CN101528227A (zh) * 2006-09-15 2009-09-09 先灵公司 氮杂环丁酮衍生物及其使用方法
EA200900613A1 (ru) 2006-11-29 2009-10-30 Пфайзер Продактс Инк. Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US20110009443A1 (en) 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
AU2009261248A1 (en) * 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP2318370A1 (en) 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls
MY155418A (en) 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
MY151246A (en) 2009-03-11 2014-04-30 Pfizer Benzofuranyl derivatives
US20110319379A1 (en) 2009-03-11 2011-12-29 Corbett Jeffrey W Substituted Indazole Amides And Their Use As Glucokinase Activators
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
TW201038572A (en) * 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
WO2010128414A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2010141817A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898239A (zh) * 2003-10-23 2007-01-17 阿斯利康(瑞典)有限公司 新的二氮杂螺烷及其在治疗ccr8介导的疾病中的用途
WO2007007069A1 (en) * 2005-07-07 2007-01-18 Vernalis (R & D) Limited Azacyclic compounds as inhibitors of sensory neurone specific sodium channels
CN101541795A (zh) * 2006-09-15 2009-09-23 先灵公司 用于治疗疼痛、糖尿病和脂类代谢紊乱的螺-稠合氮杂环丁烷衍生物

Also Published As

Publication number Publication date
BR112012023664B1 (pt) 2020-01-28
EP2547679B1 (en) 2015-11-04
CY1118721T1 (el) 2017-07-12
US8609680B2 (en) 2013-12-17
EP2547679A1 (en) 2013-01-23
PL2547679T3 (pl) 2016-02-29
TW201144312A (en) 2011-12-16
CA2792234A1 (en) 2011-09-22
BR112012023664A2 (pt) 2016-08-16
PT2547679E (pt) 2016-01-27
WO2011114271A1 (en) 2011-09-22
AU2011228699B2 (en) 2016-05-19
SG183812A1 (en) 2012-10-30
SI2547679T1 (sl) 2015-12-31
KR20130001276A (ko) 2013-01-03
TWI410423B (zh) 2013-10-01
AU2011228699A1 (en) 2012-09-20
PH12012501800A1 (en) 2012-12-10
DK2547679T3 (en) 2016-01-11
US20140080756A1 (en) 2014-03-20
RU2524341C2 (ru) 2014-07-27
CA2792234C (en) 2014-05-27
AR080688A1 (es) 2012-05-02
CN102939290A (zh) 2013-02-20
MX2012010772A (es) 2012-11-06
WO2011114271A8 (en) 2012-11-08
US20110230461A1 (en) 2011-09-22
IL221952A (en) 2016-02-29
HRP20151232T1 (hr) 2015-12-18
JP5496409B2 (ja) 2014-05-21
ME02330B (me) 2016-06-20
RU2012137489A (ru) 2014-04-27
KR101455917B1 (ko) 2014-11-03
JP2013522354A (ja) 2013-06-13
RS54383B1 (sr) 2016-04-28
HUE025774T2 (en) 2016-05-30
ES2557895T3 (es) 2016-01-29
HK1182094A1 (zh) 2013-11-22

Similar Documents

Publication Publication Date Title
CN102939290B (zh) 2,3-二氢-1h-茚-1-基-2,7-二氮杂螺[3.5]壬烷衍生物及其作为生长激素释放肽受体的拮抗剂或反向激动剂的用途
CN106117205B (zh) 用作乙酰辅酶a羧化酶抑制剂类的吡唑并螺酮衍生物
CN103189377B (zh) N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
JP2015515472A (ja) ジアシルグリセロールアシルトランスフェラーゼ2阻害薬
WO2021233236A1 (zh) 取代的杂芳基化合物及其组合物和用途
HK1182094B (en) 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
JP7573009B2 (ja) メラノコルチン4受容体アンタゴニストとしてのスピロ化合物およびそれらの使用
CN109928971A (zh) 芳基取代的氨基四氢吡喃类化合物及其用途
US20240238425A1 (en) HSD17B13 Inhibitors and/or Degraders
HK1229322A1 (en) Pyrazolospiroketone derivatives for ues as acetyl-coa carboxylase inhibitors
HK1190154A (en) Pyrazolospiroketone derivatives for ues as acetyl-coa carboxylase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1182094

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1182094

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150916

Termination date: 20210311